Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice

作者：Salari Farhad; Varasteh Abdol Reza; Vahedi Fatemeh; Hashemi Maryam; Sankian Mojtaba^*

来源：International Immunopharmacology, 2015, 29(2): 672-678.

DOI：10.1016/j.intimp.2015.09.011

• Sublingual immunotherapy (SLIT)
• IgE
• Poly (lactic-co-glycolic) acid (PLGA)
• Nanoparticles
• Recombinant allergen

The goal of this study was to investigate whether poly (lactic-co-glycolic) acid (PLGA) nanoparticles could enhance sublingual immunotherapy (SLIT) efficacy. BALB/c mice sensitized to rChe a 3 were treated sublingually either with soluble rChe a 3 (100 mu g/dose) or PLGA-encapsulated rChe a 3 (5, 25, or 50 mu g/dose). SLIT with PLGA-encapsulated rChe a 3 (equivalent to 25 and 5014 rChe a 3 per dose) led to significantly increased antigen-specific IgG2a, along with no effect on allergen-specific IgE and IgG1 antibody levels. In addition, interleukin 4 (IL-4) levels in restimulated splenocytes were significantly less, while interferon-gamma (IFN-gamma) interleukin-10 (IL-10), and transforming growth factor-beta (TGF-beta) levels, as well as Foxp3 expression, were significantly greater than in the control groups. Our findings suggest that PLGA nanoparticle-based vaccination may help rational development of sublingual immunotherapy through reduction of the needed allergen doses and also significantly enhanced systemic T regulatory (Treg) and T helper 1 (Th1) immune responses.

• 出版日期2015-12